Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026
Financial Post ·
Perioperative toripalimab plus chemotherapy demonstrated significant and durable improvements in event-free survival and overall survival in patients with resectable stage II-III non-small cell lung cancer. SHANGHAI, Oct. 27, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization […]
SHANGHAI, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the final analysis results from the Phase 3 NEOTORCH study (NCT04158440) were presented during an oral session at the 2026 European Society for Medical Oncology (ESMO) Congress (Abstract No. LBA64) and simultaneously published in Annals of Oncology . Professor Shun LU and Professor Ziming LI from Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine served as the corresponding author and first author of the publication, respectively. Read More